(Q40602865)

21 September 2017

1 reference

title

Recent developments in radioimmunotherapy (English)

1 reference

21 September 2017

Harrington KJ

1

1 reference

PubMed ID

7873487

21 September 2017

Epenetos AA

series ordinal

2

1 reference

21 September 2017

1 January 1994

1 reference

21 September 2017

1 reference

21 September 2017

6

1 reference

21 September 2017

6

1 reference

21 September 2017

391-398

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Cell and environment interactions in tumor microregions: the multicell spheroid model

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Selection of reagents for human radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Estimates of dose to intraperitoneal micrometastases from alpha and beta emitters in radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Comparisons of the efficacy of 186Re- and 131I-labeled antibody in multicell spheroids

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Studies directed toward the use of antibodies as carriers of radioactivity for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Monoclonal antibodies in the management of ovarian cancer. A clinical perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Comparison of the distribution and binding of monoclonal antibodies labeled with 131-iodine or 111-indium

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

1 reference

7 January 2021

Metastatic colon cancer: correlation of oxygen levels with I-131 F(ab')2 uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Transport of molecules across tumor vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

A longitudinal study of antigen expression in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Modulation of antigen expression in human tumor cell populations

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Radiobiological aspects of low dose rates in radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Sensitization processes in human tumor cells during protracted irradiation: possible exploitation in the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Immunotherapy of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Improved survival for hepatocellular cancer with combination surgery and multimodality treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Multi-modality treatment of primary nonresectable intrahepatic cholangiocarcinoma with 131I anti-CEA--a Radiation Therapy Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Prospects for the Management of Non-Small-Cell Carcinoma of the Lung with Monoclonal Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Progress in radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Antibody-guided irradiation of malignant pleural and pericardial effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Radioactive chromic phosphate suspension: studies on distribution, dose absorption, and effective therapeutic radiation in phantoms, dogs, and patients

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Radioactivity in blood and urine following intraperitoneal instillation of chromic phosphate in patients with and without ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Intraperitoneal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980193-1

7 January 2021

10.1016/S0936-6555(05)80193-1

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

7873487